GSK, ovarian cancer and Jemperli
Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...
Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...
This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
GSK's combined drugs Jemperli and Zejula met its primary goal of progression-free survival in patients with first line advanced ovarian cancer in a late-stage trial. The British drug maker said ...
GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...
GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.
GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback